BAX
$16.15-0.51 (-3.06%)
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceutica...
Recent News
How Is Baxter's Stock Performance Compared to Other Medical Devices Stocks?
Baxter has notably underperformed the Medical Devices industry over the past year, and analysts are cautious about the stock’s prospects.
Baxter CFO Joel Grade steps down
Grade is leaving after a two-year stint defined by changes to Baxter’s business, including the sale of its kidney care unit.
1 Unprofitable Stock with Impressive Fundamentals and 2 That Underwhelm
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Assessing Baxter International (BAX) Valuation After Downgrades And Novum LVP Legal Scrutiny
Baxter International (BAX) is back in focus after a cluster of analyst downgrades and fresh legal investigations into alleged fiduciary breaches, supply chain disclosures, and Novum LVP product safety raised new questions for shareholders. See our latest analysis for Baxter International. The recent cluster of downgrades and legal headlines has coincided with a 12.1% 1 month share price decline and a 49.0% 1 year total shareholder return loss, signalling that momentum has been fading rather...
The Bull Case For Baxter International (BAX) Could Change Following New Governance And Safety Probes – Learn Why
In recent days, Baxter International has faced renewed legal scrutiny as law firms announced investigations into alleged governance failures, product safety misstatements around its Novum LVP infusion product, and prior concealment of supply chain disruptions that may have affected earnings projections. At the same time, analysts have grown more cautious and produced mixed views on Baxter’s prospects, underscoring how regulatory and legal uncertainty is increasingly shaping perceptions of...